Two 59%+ winners, four above 25% in Aug – How this AI model keeps picking winners
AUSTIN - Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a $75 million market cap clinical-stage pharmaceutical company with a strong liquidity position and current ratio of 25.29, announced Wednesday that its Board of Directors has approved a reverse stock split as part of a going private transaction, following a recommendation from a Special Committee of independent directors.
The clinical-stage pharmaceutical company, which develops solutions for cannabis-induced toxic effects, plans to implement a reverse stock split at a ratio between 1-for-2,500 and 1-for-7,500, with the exact ratio to be determined by the Board.
Under the proposed transaction, shareholders owning fewer than the minimum threshold of shares (between 2,500 and 7,500 depending on the final ratio) will receive $3.50 in cash per pre-split share and will no longer remain stockholders. This price represents a 91% premium over the company’s July 22 closing price. According to InvestingPro data, the stock has shown strong momentum with a 14.37% return over the past week, while typically moving counter to broader market trends with a beta of -0.99.
Shareholders owning more than the minimum threshold will continue to hold one post-split share for every minimum number of pre-split shares they own, plus cash for any fractional shares.
The company stated that the costs of being a public reporting company have become "too burdensome" given its strategy to develop product candidates, reduce operating costs, and maximize stockholder value. InvestingPro analysis suggests the stock is currently trading above its Fair Value, with 8 additional key insights available to subscribers regarding the company’s financial health and future prospects.
The reverse stock split is subject to stockholder approval and other conditions, and the Board may abandon the proposed transaction if it determines it is no longer in the best interests of the company or its stockholders.
Anebulo has filed preliminary proxy materials with the SEC and intends to file definitive materials ahead of a special stockholder meeting where the proposal will be voted on.
The information in this article is based on a press release statement from Anebulo Pharmaceuticals.
In other recent news, Anebulo Pharmaceuticals reported its third-quarter financial results for fiscal year 2025, revealing a net loss of $1.7 million, or $0.04 per share. This performance matched the net loss of $1.7 million, or $0.06 per share, from the same period in the previous year. The company’s expenses for the quarter included $600,000 for research and development and $1.2 million for general and administrative costs. In addition to the financial report, Anebulo Pharmaceuticals provided updates on its clinical pipeline, highlighting the prioritization of intravenous selonabant for pediatric patients with cannabis-induced Central Nervous System depression. This strategic focus is part of the company’s ongoing efforts to advance its clinical program. Benchmark analysts responded to these developments by adjusting their outlook on Anebulo Pharmaceuticals, reducing the stock’s price target from $8.00 to $3.00. Despite this adjustment, Benchmark maintained a Speculative Buy rating for the stock. These recent developments reflect Anebulo Pharmaceuticals’ current position and ongoing initiatives.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.